Literature DB >> 25187173

H₂Me-do2pa: an attractive chelator with fast, stable and inert (nat)Bi³⁺ and ²¹³Bi³⁺ complexation for potential α-radioimmunotherapy applications.

Luís M P Lima1, Maryline Beyler, Fatima Oukhatar, Patricia Le Saec, Alain Faivre-Chauvet, Carlos Platas-Iglesias, Rita Delgado, Raphaël Tripier.   

Abstract

The complexation properties of H₂Me-do2pa towards (nat)Bi(3+) reveal a rather fast formation of the [Bi(Me-do2pa)](+) complex, which is endowed with a very high thermodynamic stability (log K(BiL) = 34.2) and presents a single non-fluxional structure in solution. X-ray diffraction and solution NMR studies showed an octadentate binding of the ligand to the metal ion. The labelling of H₂Me-do2pa with (213)Bi was performed and the resulting complex was stable in vitro, sustaining its use as an attractive alternative to taken here as a reference.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25187173     DOI: 10.1039/c4cc05529b

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  3 in total

Review 1.  Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Authors:  Eszter Boros; Jason P Holland
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

2.  Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa.

Authors:  Aohan Hu; Victoria Brown; Samantha N MacMillan; Valery Radchenko; Hua Yang; Luke Wharton; Caterina F Ramogida; Justin J Wilson
Journal:  Inorg Chem       Date:  2021-12-29       Impact factor: 5.436

Review 3.  Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

Authors:  Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.